00:56 , Jul 31, 2019 |  BC Extra  |  Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
13:54 , Apr 15, 2019 |  BC Extra  |  Financial News

Chi-Med planning Hong Kong listing

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) announced its intent to list on the Hong Kong stock exchange via a global offering. The company has submitted an application seeking a listing in 3Q19; terms have yet...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:13 , Dec 7, 2018 |  BC Week In Review  |  Company News

Chi-Med, Innovent enter global cancer partnership

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) and Innovent Biologics Inc. (HKSE:1801) will take advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib in combination with sintilimab to treat...
21:59 , Nov 30, 2018 |  BC Extra  |  Company News

Chi-Med, Innovent enter global cancer partnership

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) and Innovent Biologics Inc. (HKSE:1801) will take advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib in combination with sintilimab to treat...
20:47 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Chi-Med's fruquintinib misses OS endpoint in Phase III for third-line NSCLC

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the primary endpoint of improving overall survival (OS) vs. placebo in the Chinese Phase III FALUCA trial to treat non-small cell lung cancer....
21:52 , Nov 16, 2018 |  BC Extra  |  Clinical News

Chi-Med down on fruquintinib OS miss in third-line NSCLC

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the primary endpoint of improving overall survival vs. placebo in the Chinese Phase III FALUCA trial to treat non-small cell lung cancer. Chi-Med...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
18:17 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

ChiMed scores a China first with fruquitinib approval

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said China's National Medical Products Administration (NMPA) approved Elunate fruquintinib to treat metastatic colorectal cancer (mCRC). According to Chi-Med, the drug is the first China-discovered and developed product for...